Pharmacy Times
JULY 24, 2024
Studies show an increased prevalence of autism spectrum disorder in children of mothers; mouse models have shown links between maternal asthma and altered behavior and brain function.
STAT
JULY 24, 2024
In 1988, I became one of the first U.S. physicians certified in the new specialty of geriatric medicine, which focuses on the health care of older adults. As an idealistic and optimistic 32-year-old geriatrician, I believed that this branch of medicine would undoubtedly emerge as a vibrant field of medicine, benefiting patients and society. I was also confident that when I reached older adulthood, the health care system would be ready to care for me.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 24, 2024
Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.
STAT
JULY 24, 2024
Jiankui He, the Chinese scientist who s parked a global uproar in 2018 when he revealed he had created the first gene-edited children , is again out on his own after being dismissed from an academic post. In January 2019, provincial health authorities found that He’s human CRISPR experiments violated national regulations against gene-editing for reproductive purposes.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
JULY 24, 2024
Northwell Health has set its sights on the entertainment industry. | The health system launched a new TV and film production studio, called Northwell Studios, to produce original scripted and unscripted content leveraging its hospitals, doctors and patients, with consent.
STAT
JULY 24, 2024
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market. The San Diego-based biotech previously said it was anticipating to start a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JULY 24, 2024
A key piece of disability civil rights law could get a much-needed refresh. Sen. Bob Casey Jr. (D-Pa.) will introduce legislation Wednesday to strengthen and extend Section 508 of the Rehabilitation Act of 1973. The proposed update would boost online accessibility for people with disabilities on federal websites and significantly expand protections and working conditions for disabled federal employees.
Fierce Healthcare
JULY 24, 2024
The Centers for Medicare & Medicaid Services (CMS) has released new data on risk adjustment payments for 2023. | The Centers for Medicare & Medicaid Services has released new data on risk adjustment payments for 2023.
Drug Topics
JULY 24, 2024
PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.
BioPharm
JULY 24, 2024
GSK’s submission is supported by Phase III trials showing significant progression-free survival benefit and positive overall survival trends using Blenrep combinations compared to standard care.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
JULY 24, 2024
In part 3 of his conversation with Drug Topics on Over the Counter, Mayank Amin, PharmD, RPh, MBA, continues his inspiring story of reopening Skippack Pharmacy and details the beginnings of The Superman Pharmacist.
STAT
JULY 24, 2024
For many kids with cerebral palsy, walking is taxing. They might spend thousands of hours step-stepping in physical therapy to make walking easier. In recent years researchers have developed robots to aid this rehabilitation. A new JAMA Network Open study from a team in South Korea found that exoskeletons can improve a child’s gait, balance and motor function.
Pharmacy Times
JULY 24, 2024
In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.
STAT
JULY 24, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Several of my colleagues have joined the newsletter today to bring you the latest biopharma updates. It’s a busy news day, especially for a summer Wednesday, so let’s get straight into it.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JULY 24, 2024
Stay updated on Matteo Levisetti, the chief medical officer at CUE Biopharma, post ASCO 2024. Learn about his latest research and contributions in the field of biopharma.
STAT
JULY 24, 2024
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large phase 3 trial. The data may be enough to muster approval, but they are unlikely to quell doubts about whether the treatment can provide a cure — as had once been hoped — or a meaningful option for most patients in the U.S. and Europe with the rare blood disorder.
Pharmacy Times
JULY 24, 2024
It is essential for clinicians to properly diagnose patients with suspected AVWS and provide them proper treatment, which could be intravenous immunoglobulin.
Med Ed 101
JULY 24, 2024
In this post, I will share some questions that I would investigate from this medication list. I have many questions surrounding renal concerns given the use of sevelamer. Sevelamer is a phosphate binder that is typically used to lower phosphate levels for patients with CKD. If this patient truly has CKD and significant impairment, many […] The post Med List Review – Renal Concerns appeared first on Med Ed 101.
Drug Topics
JULY 24, 2024
Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.
pharmaphorum
JULY 24, 2024
The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them of monopolising the supply chain.
Drug Topics
JULY 24, 2024
Data will be discussed with regulatory authorities “in the coming months.
pharmaphorum
JULY 24, 2024
Explore the latest developments in the life sciences industry with a focus on patient-centred research and development (R&D) at DIA 2024. Chart new horizons and stay updated on key trends shaping the future of healthcare.
STAT
JULY 24, 2024
Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in patients with a neurological condition called essential tremor. The negative study result for the drug, called SAGE-324, is a significant setback for Sage’s neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae, an approved treatment for postpartum depression.
Fierce Pharma
JULY 24, 2024
From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. | From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S. regulator comes knocking at your facility.
pharmaphorum
JULY 24, 2024
MSD's phase 2b/3 data with clesrovimab for RSV prevention in infants sets up a challenge to Sanofi and AstraZeneca's fast-growing Beyfortus
STAT
JULY 24, 2024
Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes, and other diseases. Currently, most approved cell-based therapies use an individual’s own cells, but the next generation of these therapies will be made from donor-derived blood and tissue. That raises critical questions about how to recruit, retain, and fairly compensate donors while ensuring their safety throughout the donation process.
Fierce Pharma
JULY 24, 2024
HOPEWELL, NEW JERSEY—A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics. | A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics.
Pharmaceutical Technology
JULY 24, 2024
The crowd and panel gave Gilead a standing ovation after the full data from the Phase III PURPOSE trial was announced at AIDS 2024.
Fierce Healthcare
JULY 24, 2024
New York City-based Headway built a platform to make it both easier for patients to find a therapist and easier for therapists to accept insurance. | Headway will use the fresh capital to accelerate its planned expansion to Medicare Advantage and Medicaid, CEO Andrew Adams said.
Drug Topics
JULY 24, 2024
Check out these featured Drug Topics interviews from July 2024.
Fierce Healthcare
JULY 24, 2024
Humana's CenterWell is planning to open 23 clinics at Walmart locations in four states, the company announced on Wednesday. | Humana's CenterWell is planning to open 23 clinics at Walmart locations in four states, the company announced on Wednesday.
STAT
JULY 24, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Fierce Healthcare
JULY 24, 2024
Microsoft continues to deepen its work in healthcare AI. | Microsoft continues to deepen its work in healthcare AI. The tech giant is now collaborating with academic medical systems Mass General Brigham and the University of Wisconsin-Madison to advance AI in medical imaging.
pharmaphorum
JULY 24, 2024
Asarina Pharma has abandoned its partner search for Tourette's drug sepranolone and will go into liquidation.
Expert insights. Personalized for you.
138 
Let's personalize your content